The tweet was deleted by the author.
But we saved everything 🙂.
Day One Biopharmaceuticals has announced the completion of patient enrollment for its FIREFLY-2 clinical trial, which is assessing a new front-line therapy for pediatric low-grade glioma (pLGG).
The company states that this achievement marks a significant step toward the evolution of pLGG treatment paradigms. Further updates from the trial, including results and potential regulatory pathways, are anticipated as Day One Biopharmaceuticals continues its efforts to establish an improved standard of care for children affected by this condition.
View post on X Loading...